Latest Capital Raising News

Magmatic Resources has launched a 3,000m diamond drilling campaign at its Myall Project alongside encouraging soil sampling results at its Wellington North and Parkes projects, signaling advancing exploration momentum.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

Patrys Limited has halted plans for a Phase 1 trial of PAT-DX1 following disappointing GMP production results, pivoting its development efforts towards PAT-DX3 and exploring new partnerships.

Acrux Limited has launched its Nitroglycerin 0.4% Ointment and successfully raised nearly $4 million, positioning the specialty pharma company for sustained revenue growth.

Top End Energy has taken a major step by acquiring the Kansas Natural Hydrogen Project and advancing its exploration footprint in Australia's Beetaloo Sub-Basin, positioning itself at the forefront of natural hydrogen and unconventional gas development.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Galileo Mining Ltd’s latest quarterly cash flow report reveals a $706,000 net cash decrease amid ongoing exploration spending, while maintaining a strong cash position of $11.3 million.

Omega Oil and Gas Limited has successfully raised A$7 million in a strongly supported institutional placement, positioning the company to advance its Canyon-1H fracture stimulation and appraisal program.

Heavy Rare Earths Limited (ASX:HRE) advanced its uranium exploration footprint in South Australia with a key asset acquisition and bolstered its balance sheet through a $2.46 million capital raise during the December 2024 quarter.

Capricorn Metals delivered a robust December quarter with rising gold production, record cash flow, and strategic expansions, positioning itself strongly for FY25 targets.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.

Audeara Ltd reports a 70% jump in Q2 FY25 cash receipts, driven by new product launches and a major contract with Avedis Zildjian. The company’s expansion into Taiwan and international markets signals a promising growth trajectory.